XML 41 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2016
Segment Reporting Information [Line Items]  
Segment Information [Text Block]
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2016
 
2015
 
2016
 
2015
Segment revenue—to unaffiliated customers:
 
 
 
 
 
 
 
Human pharmaceutical products:
 
 
 
 
 
 
 
Endocrinology:
 
 
 
 
 
 
 
Humalog®
$
640.8

 
$
705.0

 
$
1,949.0

 
$
2,043.3

Forteo®
391.2

 
348.9

 
1,077.5

 
970.4

Humulin®
322.0

 
316.7

 
1,010.6

 
948.8

Trulicity®
243.6

 
73.7

 
588.5

 
136.2

Trajenta
115.4

 
92.7

 
330.8

 
255.0

Other Endocrinology
262.8

 
249.4

 
734.5

 
696.9

Total Endocrinology
1,975.8

 
1,786.4

 
5,690.9

 
5,050.6

 
 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
 
Alimta
570.4

 
628.5

 
1,741.7

 
1,865.8

Erbitux
184.6

 
85.9

 
533.3

 
308.8

Cyramza®
159.0

 
111.2

 
437.0

 
266.4

Other Oncology
33.3

 
35.7

 
100.3

 
101.8

Total Oncology
947.3

 
861.3

 
2,812.3

 
2,542.8

 
 
 
 
 
 
 
 
Cardiovascular:
 
 
 
 
 
 
 
Cialis®
588.2

 
566.1

 
1,795.3

 
1,672.3

Effient
127.7

 
132.1

 
394.3

 
382.7

Other Cardiovascular
57.6

 
61.7

 
165.4

 
183.3

Total Cardiovascular
773.5

 
759.9

 
2,355.0

 
2,238.3

 
 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
 
Cymbalta (1)
313.5

 
242.9

 
748.7

 
804.0

Strattera®
198.8

 
196.9

 
611.5

 
562.4

Zyprexa®
148.9

 
237.9

 
572.3

 
711.2

Other Neuroscience
47.3

 
46.8

 
137.4

 
136.0

Total Neuroscience
708.5

 
724.5

 
2,069.9

 
2,213.6

 
 
 
 
 
 
 
 
Other pharmaceuticals
80.4

 
48.8

 
213.0

 
168.5

Total human pharmaceutical products
4,485.5

 
4,180.9

 
13,141.1

 
12,213.8

Animal health
706.2

 
778.8

 
2,320.5

 
2,369.3

Revenue
$
5,191.7

 
$
4,959.7

 
$
15,461.6

 
$
14,583.1

 
 
 
 
 
 
 
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2016
 
2015
 
2016
 
2015
Segment profits:
 
 
 
 
 
 
 
Human pharmaceutical products
$
1,089.0

 
$
1,124.1

 
$
2,975.3

 
$
3,224.0

Animal health
104.9

 
139.8

 
464.3

 
443.1

Total segment profits
$
1,193.9

 
$
1,263.9

 
$
3,439.6

 
$
3,667.1

 
 
 
 
 
 
 
 
Reconciliation of total segment profits to consolidated income before taxes:
 
 
 
 
 
 
 
Segment profits
$
1,193.9

 
$
1,263.9

 
$
3,439.6

 
$
3,667.1

Other profits (losses):
 
 
 
 
 
 
 
Acquired in-process research and development (Note 3)
—

 
—

 
—

 
(336.0
)
Amortization of intangible assets
(177.7
)
 
(152.5
)
 
(518.8
)
 
(457.2
)
Asset impairment, restructuring, and other special charges (Note 5)
(45.5
)
 
(42.4
)
 
(234.9
)
 
(222.8
)
Venezuela charge (Note 12)
—

 
—

 
(203.9
)
 
—

Debt repurchase charges, net (2) (Note 6)
—

 
—

 
—

 
(152.7
)
Inventory fair value adjustment related to Novartis AH (Note 3)
—

 
(21.2
)
 
—

 
(153.0
)
Consolidated income before taxes
$
970.7

 
$
1,047.8

 
$
2,482.0

 
$
2,345.4


(1) Cymbalta revenues include reductions to the reserve for expected product returns of approximately $145 million and $175 million during the three and nine months ended September 30, 2016, respectively.
(2) We recognized pretax net charges of $152.7 million for the nine months ended September 30, 2015, attributable to the debt extinguishment loss of $166.7 million from the purchase and redemption of certain fixed-rate notes, partially offset by net gains from non-hedging interest rate swaps and foreign currency transactions associated with the related issuance of euro-denominated notes.